The updated systematic review by Cahill and colleagues has several new findings that are useful for clinicians. First, cytisine, a low-cost plant-derived agent from Eastern Europe, had a modest increase in quit rates across 2 high-quality trials. A previous review found that earlier trials were of low quality (1), and publication bias is likely given that the drug had been studied in regions where there was a tradition of publishing only positive research (2). Second, the authors provide estimates of the rate of SAEs with varenicline. Concerns have centered on psychiatric morbidity, suicide, and possible increases in cardiovascular events (3, 4). The results of Cahill and colleagues show a clinically important excess of 1% in the rate of SAEs with varenicline compared with placebo. One must carefully weigh the risks and benefits of varenicline compared with other therapies. Data from ongoing trials and longer-term postmarketing surveillance are needed to resolve the question of cardiovascular risk with varenicline. The review also found that varenicline is similar to nicotine replacement in efficacy. Conclusions based on this finding should take into account that cessation rates for both varenicline and nicotine replacement in the included studies were higher than are usually achieved in clinical practice. Finally, it is encouraging that lower doses of varenicline may have similar efficacy and fewer side effects compared with standard doses. Substantial cost savings for patients and health systems are possible with use of lower doses. 
Commentary
The updated systematic review by Cahill and colleagues has several new findings that are useful for clinicians. First, cytisine, a low-cost plant-derived agent from Eastern Europe, had a modest increase in quit rates across 2 high-quality trials. A previous review found that earlier trials were of low quality (1) , and publication bias is likely given that the drug had been studied in regions where there was a tradition of publishing only positive research (2). Second, the authors provide estimates of the rate of SAEs with varenicline. Concerns have centered on psychiatric morbidity, suicide, and possible increases in cardiovascular events (3, 4). The results of Cahill and colleagues show a clinically important excess of 1% in the rate of SAEs with varenicline compared with placebo. One must carefully weigh the risks and benefits of varenicline compared with other therapies. Data from ongoing trials and longer-term postmarketing surveillance are needed to resolve the question of cardiovascular risk with varenicline. The review also found that varenicline is similar to nicotine replacement in efficacy. Conclusions based on this finding should take into account that cessation rates for both varenicline and nicotine replacement in the included studies were higher than are usually achieved in clinical practice. Finally, it is encouraging that lower doses of varenicline may have similar efficacy and fewer side effects compared with standard doses. Substantial cost savings for patients and health systems are possible with use of lower doses. 
Review scope
Included studies evaluated selective nicotine receptor partial agonists in adult smokers and had ≥ 6 months of follow-up from start of treatment. Studies of lobeline were excluded. Outcomes included smoking abstinence and serious adverse events (SAEs).
Review methods
Cochrane Tobacco Addiction Review Group specialized register (which includes searches of MEDLINE, EMBASE/Excerpta Medica, PsycINFO, Web of Science, and Cochrane Central Register of Controlled Trials and hand-searches of specialist journals, conference proceedings, and reference lists of trials and reviews) and US and UK online clinical trial registries were searched in December 2011 for randomized controlled trials (RCTs). Authors of ongoing varenicline and cytosine studies were contacted. 24 RCTs met the selection criteria. Drugs assessed were varenicline (20 RCTs, n = 12 223), cytisine (3 RCTs, n = 2151), and dianicline (1 RCT, n = 602).
Main results
Meta-analysis showed that varenicline was better than placebo but did not differ from the nicotine patch for abstinence at ≥ 24 weeks; varenicline was better than bupropion at 52 weeks (Table) . Lower-dose varenicline was better than placebo and did not differ from standard-dose varenicline for smoking abstinence at 52 weeks (Table) . Varenicline increased SAEs (Table) , nausea (n = 6619, 29% vs 9%, P < 0.001), insomnia (n = 6309, 14% vs 9%, P < 0.001), abnormal dreams (n = 5585, 13% vs 4%, P < 0.001), and headache (n = 5913, 13% vs 11%, P = 0.02) more than placebo. Cytisine increased smoking abstinence more than placebo at longest follow-up (2 RCTs, n = 973, relative benefit increase [RBI] 298%, 95% CI 101 to 687); dianicline did not (1 RCT, n = 602, RBI 20%, −18 to 75 at 26 wk).
